Articles tagged with Neurodegenerative Diseases
Researchers demonstrated that 40-Hz auditory stimulation significantly elevates beta-amyloid levels in the cerebrospinal fluid of aged rhesus monkeys, with effects persisting for over five weeks. The study provides evidence supporting 40-Hz stimulation as a non-invasive therapy for Alzheimer's disease.
Researchers discovered that female brain immune cells called microglia express more interferon-related genes when responding to amyloid-β plaques, causing more harm to neuronal connections. This finding suggests a potential sex-specific treatment approach for Alzheimer's disease.
Researchers discovered that calcium alpha-ketoglutarate restores key memory-related brain functions disrupted in Alzheimer's disease. The molecule enhances synaptic plasticity, protects neurons from degenerative changes, and supports healthier cognitive ageing.
Researchers have successfully reversed Alzheimer's disease in animal models by restoring the brain's energy balance, leading to both pathological and functional recovery. The study used preclinical mouse models and human AD brains to show that maintaining proper NAD+ levels can prevent and even reverse the disease.
A comprehensive review of prior research found no evidence that menopause hormone therapy increases or decreases dementia risk in post-menopausal women. The study included data from over 1 million participants and analyzed the impact on mild cognitive impairment and Alzheimer's disease, with no significant association found.
In a new study, Northwestern scientists identified a previously unknown toxic sub-species of amyloid beta oligomers that drive brain changes in Alzheimer's disease. NU-9 decreased this toxin and reduced damage in a mouse model, suggesting it could prevent or delay the cascade of toxic events that destroy neurons.
A mouse study by Okinawa Institute of Science and Technology researchers has found that acetylcholine release is essential for breaking habits and enabling new choices to be made. The study's findings may help understand diseases such as Parkinson's disease, addiction, and obsessive-compulsive disorder.
Scientists at Salk Institute find protein CCN1, secreted by astrocytes, maintains stable neural circuits in adult brains. The discovery could lead to new therapeutics for brain injury and stroke.
Researchers investigated a combination of stem cell therapy and BDNF enhancement to treat Parkinson's disease. The strategy aims to promote neuroregeneration and functional recovery by introducing progenitor cells genetically matched to the donors, while upregulating BDNF to mitigate neuronal loss and enhance motor function.
A comprehensive review reveals tau protein plays essential roles in brain functions while driving neurodegeneration and psychopathology. Tau deficiency enhances insulin secretion, normalizing glucose levels in diabetic mouse models.
A new study suggests that midlife depression is driven by a small cluster of specific symptoms, rather than depression overall. The six symptoms are loss of self-confidence, difficulty coping with problems, and poor concentration, which can lead to reduced social engagement and decreased cognitive reserve.
CEMIP is associated with the breakdown of myelin, a protective sheath around nerve cells. Elevated levels of the enzyme inhibit myelin regeneration in people with multiple sclerosis. Researchers hope targeting CEMIP may promote central nervous system repair and slow disease progression.
A new study reveals that factors present in aged blood can accelerate the accumulation of amyloid proteins and influence behavior in an experimental mouse model of Alzheimer's. The study found more than 250 differentially expressed proteins linked to synaptic functions, endocannabinoid signaling, and calcium channels.
Researchers developed an AI tool to identify patients with undiagnosed Alzheimer's disease using electronic health records, addressing underdiagnosis and healthcare inequities. The model achieved sensitivity rates of 77-81% across diverse populations, promoting fairness while maintaining high accuracy.
Scientists at Michigan Medicine have developed machine learning models that can analyze blood samples for biomarkers to detect ALS earlier and predict disease severity. The models show promising results, with predictions accurate up to 91% in some cases, and could lead to improved diagnostic accuracy and treatment options.
The International Linked Clinical Trials Program aims to change that by supporting and facilitating clinical trials of potentially disease-modifying treatments. Over 6,800 people with Parkinson's have participated in these trials, and approximately 40% of prioritized drugs have been approved for clinical trials.
Researchers at Florida Atlantic University have developed a deep learning model that detects and evaluates Alzheimer's disease (AD) and frontotemporal dementia (FTD) using EEG brainwave analysis. The model achieved over 90% accuracy in distinguishing individuals with dementia from cognitively normal participants.
The UT Health San Antonio Center for Brain Health brings together expertise in dozens of disorders, emphasizing education, family support and community connection. The center is part of ongoing national research initiatives, including a study on ALS and HEALEY ALS Platform Trial.
This study found that older mice blood worsens Alzheimer’s-related changes, while younger blood improves memory and cognitive function. The researchers identified key proteins involved in neurodegeneration and inflammation, suggesting new avenues for targeting blood-borne factors to slow or modify disease progression.
A new study highlights five ways microplastics can trigger inflammation and damage in the brain, including immune cell activity and oxidative stress. Microplastics weaken the blood–brain barrier, causing immune cells to attack them and leading to further damage.
Researchers at Helmholtz Munich uncovered a mechanism that protects nerve cells from premature cell death, known as ferroptosis. A single mutation in the GPX4 gene disrupts its function, leading to severe neurodegeneration in children with early-onset dementia.
The EBRAINS Summit 2025 will bring together experts to assess how neuroscience can drive medical progress, digital innovation, and responsible data use. Preliminary results from the EPINOV clinical trial, integrating virtual brain technology for epilepsy surgery planning, will be presented.
A recent study found that the protein TDP43 regulates genes responsible for fixing DNA mistakes, which can lead to cancer when overactive. The discovery could lead to new treatments by controlling overactive DNA repair, offering a therapeutic strategy for diseases such as ALS and dementia.
Dr. Paul Lucassen's research on adult neurogenesis reveals the link between early life experiences, lifestyle factors, and depression/dementia risk. His work has implications for therapeutic approaches to brain health and disease.
A new method developed by Penn State researchers improves the analysis of genetic data, identifying more genes associated with neurodegenerative diseases like Alzheimer's and ALS. The technique, BASIC, integrates both bulk tissue samples and single-cell data to uncover shared genetic effects across different cell types.
A large Korean cohort study reveals a link between restless legs syndrome and Parkinson's disease, highlighting opportunities for early detection. Dopamine-agonist therapy may reduce the risk of developing PD in RLS patients, according to the study's findings.
Researchers discover GFAP's crucial role in regulating mitochondrial fusion and fission, a dynamic process that meets cells' energy needs. The study sheds light on Alexander disease, a genetic disorder caused by GFAP mutations, providing potential new avenues for therapies.
The USC Epstein Family Alzheimer’s Therapeutic Research Institute is leading the charge against Alzheimer’s with advances in blood tests and treatments. Researchers aim to develop effective preventive therapies within the next decade.
Researchers discovered that brain enzyme OTULIN regulates tau protein accumulation and has implications for treating neurodegenerative diseases. The study revealed OTULIN's role in controlling gene expression and RNA metabolism, suggesting a potential therapeutic target.
Researchers identified biological markers of inflammation, liver stress, and early damage to brain cells in young adults with obesity. Low blood levels of choline, essential for liver health and long-term brain function, were also found. These findings suggest that metabolic stress and inflammation may begin far earlier than expected.
Researchers have identified a new immune process that clears toxic amyloid plaques and delays cognitive decline in Alzheimer's disease. The 'Fc fragment' of the monoclonal antibody Lecanemab activates microglia, the brain's immune cells, to remove plaques more efficiently.
Researchers aim to strengthen and retrain swallowing function in people with early Parkinson's disease using a novel treatment program. The three-year study will test the effectiveness of SwallowFIT on swallowing difficulties, aspiration rates and nutritional status.
Researchers identify a rare gene mutation that appears to protect the brain's immune cells from damage caused by Alzheimer's disease. The study reveals how this mutation can confer resilience on the brain, potentially leading to new therapeutic approaches.
A new study by UC San Francisco combines genetic risk with cardiovascular disease risk factors to predict who is more likely to develop dementia. The expanded view may help those worried about dementia, as lifestyle changes and improved control of illnesses can reduce brain damage and potentially delay or prevent symptoms.
Researchers found that oral arginine significantly reduces amyloid buildup and neuroinflammation, suggesting a safe and low-cost therapeutic approach for Alzheimer's disease. Arginine also improves behavioral performance and reduces pro-inflammatory cytokine genes.
A study published in Alzheimer's & Dementia found that long-term pharmacological treatment improves memory alterations and inflammation in mice models for Down syndrome. The treatment targets the CB1 receptor, which is involved in neuronal connections and memory, and shows positive results even when age-related neurodegeneration is added.
A systematic review and meta-analysis found that lithium supplementation did not significantly improve cognitive function in individuals with mild cognitive impairment or Alzheimer's disease. Alternative formulations like LIT-O may be a potential alternative to harness lithium's neuroprotective properties more efficiently.
A study by NTU Singapore researchers found that enlarged perivascular spaces, or 'clogged drains', in the brain are a likely early-warning sign of Alzheimer's disease. The condition can be visually identified on routine MRI scans, complementing existing methods to detect Alzheimer's earlier.
A study from Gladstone Institutes finds that dysfunctional mitochondria can initiate Parkinson's disease. The researchers used a unique mouse model to demonstrate the link between mitochondrial dysfunction and energy breakdown in cells, shedding light on potential new treatments.
Researchers have successfully engineered functional brain-like tissue without animal-derived materials, opening doors to more controlled and humane neurological drug testing. The new material functions as a scaffold for donor brain cells and can be used to model traumatic brain injuries or neurological diseases like Alzheimer's.
A team from Tokyo Metropolitan University has identified a crucial precursor structure in the formation of tau protein fibrils, mirroring the crystallization of polymers. Dissolving these clusters prevents fibril formation, suggesting a new paradigm for treating neurodegenerative diseases.
A preclinical study from Weill Cornell Medicine investigators found that hypertension impairs blood vessels, neurons and white matter in the brain before causing a measurable rise in blood pressure. Gene expression changes in individual brain cells could interfere with thinking and memory.
Researchers at UGA engineered a live bacterium to deliver Levodopa steadily from the gut to the brain, alleviating motor deficits in models of Parkinson's disease. This breakthrough could lead to fewer pills, steadier symptom control, and better quality of life for patients.
A comprehensive review identifies exosomes as critical mediators in the process of obstructive sleep apnea (OSA)-related diseases. OSA-induced intermittent hypoxia and sleep fragmentation alter exosome secretion and content, disrupting cell function and leading to various comorbidities.
The UT Health San Antonio Center for Brain Health is a $100 million facility that brings together clinical care, diagnostics and research under one roof. The center will redefine treatment of conditions including Alzheimer's, dementia, stroke and Parkinson's with multidisciplinary care teams.
A study by Osaka Metropolitan University found that lecanemab treatment does not change short-term waste clearance function in Alzheimer's patients. The glymphatic system, which carries away metabolic waste like Aβ, is already damaged in AD patients, and treatment may not be enough to restore lost function.
The URI team developed a cost-effective, easy-to-use tabletop device to generate pressure waves mimicking blasts that cause neurodegeneration. The device helps researchers study the development and progression of neurodegenerative diseases, including TBI-related neurodegenerative disease.
A new study reveals that increasing NAD⁺ levels corrects RNA splicing mistakes, improving brain function and restoring memory in animal models of Alzheimer's disease. The researchers discovered a previously unidentified pathway involving the protein EVA1C, which plays a crucial role in correcting tau-related neuronal damage.
Researchers uncover a unique structural motif in the tail region of kinesin-2 that acts as a molecular 'connector,' allowing the motor to correctly recognize and transport its cargo inside cells. The discovery provides new insights into brain transport and diseases, paving the way for diagnostic and therapeutic approaches.
A new study from Texas Biomedical Research Institute found that low-dose THC significantly reduced side effects and inflammation caused by HIV and antiretroviral therapy. The treatment also increased serotonin levels, lowered cholesterol and toxic bile acids, and improved cardiovascular health.
Scientists discovered that eIF1A and eIF5B suppress toxic protein synthesis implicated in frontotemporal dementia and amyotrophic lateral sclerosis. The study sheds light on the mechanisms behind RAN translation, a process linked to neurodegenerative disorders.
A new study found that middle-aged people with higher levels of cardiac troponin I in their blood were more likely to develop dementia in later life. The study also found that damage to the brain seen in people with dementia accumulates slowly over decades before symptoms develop.
High-volume noise exposure in a mouse model of early-stage Parkinson's disease slowed movement and reduced balance, suggesting a connection between sound processing and movement areas. Chronic noise exposure mimicked Parkinsonian symptoms by damaging dopamine-producing cells.
Researchers at OIST discover a common molecular cascade disrupting brain signaling in both Alzheimer's and Parkinson's diseases. They identify a shared mechanism affecting synaptic vesicle recycling, leading to impaired communication between brain cells.
A recent study from Houston Methodist reveals how Alzheimer's can disrupt the connection between nerves and blood vessels in fat tissue, worsening heart and metabolic conditions. The research highlights a potential link between neurodegeneration and cardiovascular and metabolic disorders.
Researchers at the Medical University of South Carolina have identified a previously unknown hub in the brain's lymphatic drainage system, which helps remove waste from the brain. The study provides evidence of a slow-moving fluid flow through true lymphatic vessels, rather than blood vessels.
A new study published in Science finds CTE shares genetic similarities with Alzheimer's disease, including DNA damage and tau protein buildup in the brain. Researchers used single-cell genome sequencing to identify somatic mutations in neurons from patients with CTE, revealing abnormal patterns of damage similar to those seen in AD.
This review synthesizes current knowledge on how gut microbiota dysbiosis influences neuroinflammation, blood-brain barrier integrity, and immune homeostasis. Dysregulation of the gut-brain-immune axis in neurodegenerative diseases drives inflammation, synaptic dysfunction, and neuronal damage.
Researchers have developed a blood test that detects Parkinson's disease by analyzing the activity of immune cells. The study found 22 genes whose expression was altered in patients with Parkinson's, suggesting potential diagnostic markers and insights into the disease's mechanisms.
A small study found that five volunteers with late-onset Alzheimer's disease showed significant improvements in cognitive tests and decreased biomarker tau proteins after two years of receiving 40Hz light and sound stimulation. This suggests that the therapy may slow cognitive decline and have direct biological impacts on Alzheimer's p...